The major effort in the treatment of rhabdomyolysis is directed toward prevention of renal failure. AKI has been observed in 10% to 60% of patients presenting with rhabdomyolysis,3,4,6,40,42,43,46 and 10% of AKI has been attributed to rhabdomyolysis.10 The cause of muscle injury, intravascular volume status, patient comorbidities, and initial laboratory results may be helpful in determining the risk of progression to AKI. Although CK, myoglobin, potassium, bicarbonate, albumin, lactate dehydrogenase, and creatinine levels at presentation have been evaluated, no single marker or predictive model has been able to reliably assess the risk of AKI. The reason for this difficulty is at least twofold: the multifactorial nature of kidney injury, with rhabdomyolysis being only one of the contributing factors, and the heterogeneity in the causes of rhabdomyolysis. Suggested markers and models of AKI are derived from the results of single-center retrospective studies and are difficult to generalize. Serial trends of laboratory markers may be more appropriate than single results to assess the risk of AKI.